Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model
Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission
British Journal of Haematology
Review of 'minitransplantation': nonmyeloablative allogeneic hematopoietic stem cell transplantation
International Journal of Hematology
Adoptive immunotherapy against kidney targets in dog-leukocyte antigen-identical mixed hematopoietic canine chimeras
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclo
Prevention of graft-vs.-host disease.
Expert Opin Pharmacother., Aug;13(12):1737-50 (2012)
Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation.
Biol. Blood Marrow Transplant., Nov;17(11):1594-601 (2011)
Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia.
Blood., Aug;118(5):1421-8 (2011)
Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.
Blood., Jul;118(2):456-63 (2011)
Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.
Biol. Blood Marrow Transplant., Oct;17(10):1537-45 (2011)
â¹â°Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.
Blood., Jul;118(4):1132-9 (2011)
A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.
Biol. Blood Marrow Transplant., Jul;17(7):1088-92 (2011)
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.
Blood., Mar;117(11):3214-9 (2011)
A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation.
Biol. Blood Marrow Transplant., Sep;17(9):1308-15 (2011)
Role of comorbidities in optimizing decision-making for allogeneic hematopoietic cell transplantation.
Mediterr J Hematol Infect Dis., 2(2):e2010015 (2010)
Allogeneic hematopoietic cell transplantation: the state of the art.
Expert Rev Hematol., Jun;3(3):285-99 (2010)
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.
J. Clin. Oncol., Feb;28(6):1011-6 (2010)
CCR5 expression on cells from HLA-matched unrelated marrow donors and graft-versus-host disease.
Biol. Blood Marrow Transplant., Jan;16(1):132-3 (2010)
Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease.
Biol. Blood Marrow Transplant., Mar;16(3):311-9 (2010)
Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation.
Blood., Feb;115(6):1288-95 (2010)